Nang Kuang Pharmaceutical Co Ltd

Nang Kuang Pharmaceutical Co Ltd maintains a conservative capital structure with a debt-to-equity ratio of 0.26, indicating a relatively low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.4, suggesting it can cover short-term obligations but with limited surplus. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints. Profitability metrics show a return on equity (ROE) of 9.84% and a return on assets (ROA) of 6.39%, both of which are below the industry median for pharmaceutical firms, indicating room for improvement in asset utilization and shareholder returns. The company's operating margin is 13.63%, which is in line with the industry average, but its net margin of 11.3% is slightly below the median, suggesting higher-than-average operating expenses or tax burdens. The company's revenue is concentrated in a few product lines, with a significant portion derived from injections and capsules, and geographic exposure is primarily domestic, with limited international diversification. This concentration increases vulnerability to regulatory changes or domestic market shifts. Outlook for the current fiscal year shows a projected revenue growth of 2.1%, with a slight decline in operating income expected due to rising raw material costs. For the next fiscal year, the company anticipates a 3.4% revenue increase, driven by expansion in the domestic medical equipment market. Risk factors include medium liquidity risk due to negative net cash and a low dilution potential, with no significant share issuance expected in the near term. The company has not made any recent material capital commitments or issued new shares, and no dilution sources are currently identified. Recent filings and transcripts indicate the company is focusing on cost optimization and product diversification to mitigate supply chain risks. No major regulatory or legal issues have been disclosed in the latest reports.